Registration standards reason behind potential de-registration of Nevirapine
Living with AIDS Programme 137
The MCC says it is within its rights as a regulatory authority, just like America's FDA, to demand access to all information collated during the Uganda HIVNET 012 study on the efficacy of Nevirapine in order to support the continued registration of the drug for PMTCT in South Africa.
Living with AIDS Programme 137


